Alterity Therapeutics (ASX:ATH) has announced that the US FDA has granted fast track designation for ATH434 for treating Multiple System Atrophy. …
FDA grants fast track designation for Alterity's ATH434 to treat multiple aystem atrophy
May 5, 2025 Australian Biotech
Latest Video
New Stories
-
Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy
May 5, 2025 - - Australian Biotech -
Arovella options advances Baylor College of technology to enhance iNKT cell platform
May 5, 2025 - - Australian Biotech -
FDA grants fast track designation for Alterity's ATH434 to treat multiple aystem atrophy
May 5, 2025 - - Australian Biotech -
New immune therapy treatment option for women diagnosed with advanced endometrial cancer
May 4, 2025 - - Latest News -
Stakeholders should hope for continuity in the health portfolio
May 4, 2025 - - Latest News -
UCB welcomes the PBS listing of dual-acting anti-seizure medication
May 4, 2025 - - Latest News -
Pharma, pharmacy and biotech congratulate Government for re-election
May 4, 2025 - - Latest News